Clinical Trials Logo

Unknown Primary Tumors clinical trials

View clinical trials related to Unknown Primary Tumors.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03418480 Completed - Clinical trials for Head and Neck Neoplasm

HARE-40: HPV Anti-CD40 RNA vaccinE

HARE-40
Start date: April 11, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

HARE-40 is a phase I/II vaccine dose escalation study with two different arms: Arm 1A will perform intrapatient dose escalation in patients with previously treated HPV16+ Head & Neck Cancer using two dose cohorts to establish a safe, tolerable and recommended dose of HPV vaccine. Arm 1B will perform intrapatient dose escalation in patients with advanced HPV16+ cancer (head and neck, anogenital, penile, cervical and other) using a single cohort to establish a safe, tolerable and recommended dose of HPV vaccine.

NCT ID: NCT02607202 Completed - Clinical trials for Unknown Primary Tumors

A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

AGNOSTOS
Start date: March 2015
Phase: Phase 2
Study type: Interventional

Agnostos Trial is a multicentric phase 2 randomized trial with a 'pick-the-winner design' in chemonaive patients with cancer of unknown primary. It will assess the efficacy of the two best active single agent - carboplatin or gemcitabine - added to an innovative taxane back bone (nab-Paclitaxel). Agnostos trial is a part of a larger clinical and translational initiative to improve the outlook of patients with cancer of unknown primary through evaluation of novel chemotherapeutic regimens.